Macrolide Antibiotics Market Report 2025

This Macrolide Antibiotics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The macrolide antibiotics market size has grown rapidly in recent years. It will grow from $59.07 billion in 2024 to $66.02 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increasing antibiotic resistance, approvals for new formulations, a rise in infectious diseases, and government and healthcare initiatives.

The macrolide antibiotics market size is expected to see rapid growth in the next few years. It will grow to $102.09 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to a rise in respiratory infections due to factors like arise in respiratory infections, rise in combination therapies, an increase in the global geriatric population, increased awareness and diagnostics, and growth in telemedicine and online pharmacy services. Major trends in the forecast period include advancements in drug delivery systems and formulations, the development of novel macrolide antibiotics, advancements in telemedicine and remote healthcare services, and the development of eco-friendly manufacturing processes for macrolide antibiotics.

The growth of the macrolide antibiotics market is expected to be driven by the increasing prevalence of skin infections in the coming years. Skin infections occur when harmful microorganisms invade the skin, causing inflammation and often accompanied by symptoms such as redness, swelling, and pain. Factors contributing to the rise in skin infections include poor hygiene practices, compromised immune systems, exposure to environmental pollutants, antibiotic resistance, and inadequate wound care. Macrolide antibiotics are commonly prescribed to treat skin infections caused by bacteria such as Staphylococcus aureus or Streptococcus pyogenes, especially in cases of penicillin allergy or resistance. For example, according to the UK Health Security Agency (UKHSA) in September 2022, the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia cases attributed to skin and soft tissue infections increased from 25.7% to 33.7% between April 2020 to March 2021 and April 2021 to March 2022. Similarly, for Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia cases, the percentage rose from 27.2% to 28.5% over the same period, indicating a rising trend in skin infections driving the macrolide antibiotics market.

Major companies in the macrolide antibiotic market are increasingly focusing on developing generic formulations to improve accessibility, reduce treatment costs, and expand their market presence. Generic versions of macrolide antibiotics contain the same active ingredients, dosage, and strength as their branded counterparts but are typically sold at lower prices. For example, in May 2022, Phantom Pharmaceuticals, a US-based pharmaceutical company, launched two new products - VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK - designed to treat Helicobacter pylori (H. pylori) infection in adults. The VOQUEZNA TRIPLE PAK contains vonoprazan (a potassium-competitive acid blocker or PCAB), amoxicillin, and clarithromycin, while the VOQUEZNA DUAL PAK includes vonoprazan and amoxicillin. The introduction of vonoprazan marks a significant advancement, as it represents the first new class of acid suppressants approved in the U.S. in over 30 years. This move towards generic formulations helps improve treatment accessibility and affordability for patients while expanding the market for macrolide antibiotics.

In April 2024, Aztiq, an Iceland-based long-term investment fund, acquired Alvogen Emerging Markets Holdings Limited from PTT Public Company Limited for an undisclosed sum. The acquisition aims to accelerate Adalvo's growth and expansion by leveraging the combined strengths of Aztiq and Innobic (Asia), PTT's wholly-owned Life Science arm. Adalvo, a US-based pharmaceutical company, specializes in providing macrolide antibiotics.

Major companies operating in the macrolide antibiotics market are Pfizer Inc., Roche Holding AG, Merck Sharp & Dohme Corp, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Eli Lily and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Daiichi Sankyō, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Zhejiang Guobang Pharmaceutical Co. Ltd., Fresenius Kabi USA, WOCKHARDT, Crescent Pharma Limited, Wellona Pharma Private Limited.

North America was the largest region in the macrolide antibiotics market in 2024. The regions covered in the macrolide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macrolide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Macrolide antibiotics are characterized by a macrocyclic lactone ring to which one or more sugars are attached. They exert their antibacterial effect by binding to the 50S ribosomal subunit, thereby inhibiting bacterial protein synthesis. This mechanism makes them effective against a wide range of Gram-positive bacteria and some Gram-negative bacteria.

Azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin are the main types of macrolide antibiotics. Azithromycin, for instance, inhibits bacterial growth by disrupting protein synthesis. It is used to treat respiratory tract infections, skin infections, sexually transmitted infections, gastrointestinal infections, among others. Azithromycin can be administered orally, parenterally, or through other routes. It is distributed through hospital pharmacies, retail drug stores, and online providers, and is utilized by various end users such as hospitals, dermatology clinics, outpatient clinics, ambulatory centers, and research laboratories.

The macrolide antibiotics market research report is one of a series of new reports that provides macrolide antibiotics market statistics, including macrolide antibiotics industry global market size, regional shares, competitors with a macrolide antibiotics market share, detailed macrolide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the macrolide antibiotics industry. This macrolide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The macrolide antibiotics market consists of sales of oral tablets and capsules such as dirithromycin, josamycin, spiramycin, and roxithromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.